Stay updated with breaking news from Nasdaq Mbot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Microbot Medical (NASDAQ:MBOT – Free Report) had its target price decreased by HC Wainwright from $8.00 to $7.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Microbot Medical’s Q1 2024 earnings at ($0.17) EPS, Q2 2024 […]
Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 27,900 shares, a decrease of 53.0% from the December 15th total of 59,300 shares. Based on an average daily volume of 882,600 shares, […]
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study...
The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the...
BRAINTREE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System,...